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Abstract
Background: Vaccination against hepatitis B virus infection (HBV) is safe and effective; however, vaccine-induced antibody
level wanes over time. Peak vaccine-induced anti-HBs level is directly related to antibody decay, as well as risk of infection
and persistent carriage despite vaccination. We investigated the role of host genetic factors in long-term immunity against
HBV infection based on peak anti-HBs level and seroconversion to anti-HBc.
Methods: We analyzed 715 SNP across 133 candidate genes in 662 infant vaccinees from The Gambia, assessing peak
vaccine-induced anti-HBs level and core antibody (anti-HBc) status, whilst adjusting for covariates. A replication study
comprised 43 SNPs in a further 393 individuals.
Results: In our initial screen we found variation in IFNG, MAPK8, and IL10RA to affect peak anti-HBs level (GMTratio of ,0.6
or .1.5 and P#0.001) and lesser associations in other genes. Odds of core-conversion was associated with variation in
CD163. A coding change in ITGAL (R719V) with likely functional relevance showed evidence of association with increased
peak anti-HBs level in both screens (1st screen: s595_22 GMTratio 1.71, P=0.013; 2nd screen: s595_22 GMTratio 2.15,
P=0.011).
Conclusion: This is to our knowledge the largest study to date assessing genetic determinants of HBV vaccine-induced
immunity. We report on associations with anti-HBs level, which is directly related to durability of antibody level and
predictive of vaccine efficacy long-term. A coding change in ITGAL, which plays a central role in immune cell interaction,
was shown to exert beneficial effects on induction of peak antibody level in response to HBV vaccination. Variation in this
gene does not appear to have been studied in relation to immune responses to viral or vaccine challenges previously. Our
findings suggest that genetic variation in loci other than the HLA region affect immunity induced by HBV vaccination.
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Introduction
Persistent hepatitis B virus (HBV) infection affects 350 million
people world-wide, with highest endemicity in Sub-Saharan Africa
and China. It is estimated that around half a million die every year
from end stage complications of persistent infection [1]. Long-term
studies in The Gambia aim to answer the question as to whether
prevention of (early) HBV infection through infant vaccination
reduces the incidence of persistent carriage and of subsequent
hepatocellular carcinoma (HCC) in later life [2–9]. In The
Gambia vaccination was introduced in the mid 1980s and has
been demonstrated to be safe and effective, however, the level of
HBV vaccine-induced antibody decays exponentially over time,
and this is irrespectively of the population immunised [10]. The
peak antibody level attained after vaccination is directly related to
this uniform decay, as shown experimentally and through
modelling [11,12]. Hence we have used peak anti-HBs as a
surrogate for durability since we can predict from it the antibody
level at any time point afterwards. High peak anti-HBs level
correlates directly with protection against infection and persistent
carriage [9]. So whilst the anti-HBs level wanes with time since
vaccination, the proportion of core-antibody (anti-HBc) positive
individuals, i.e. those infected despite vaccination, increases and
was shown to be .15% in the most recent surveys carried out
(with up to 19 years of follow-up) [9,12]. This happens at a time
when the risk of exposure is increasing due to the onset of sexual
activity.
Little is known about host genetic determinants of immunity
induced by infant HBV vaccination per se, and even less about the
role of genetic variation in determining the duration of vaccine-
induced immunity. Family and twin studies have established that
genetic variability influences vaccine immunogenicity [13–15].
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1898Ho ¨hler et al concluded from a twin study assessing the heritability
of HBsAg vaccine response that genetic factors have a strong
influence, with variation in the MHC playing an important role,
but suggesting that more than half the heritability is determined by
non-MHC genes [16]. In The Gambia Newport and colleagues
assessed the heritability of immune responses to several infant
vaccines in twins and showed that the genetic contribution to
antibody responses varied depending on the vaccine; for anti-HBs
response the observed heritability was relatively high (77%) [17].
A number of studies have linked HLA class I, II and III
variation to non-response or low response to hepatitis B vaccine
[18–28]. The most consistent findings regarding high response are
associations with DRB1*01 (DR1), DRB1*11 (DR5), DRB1*15
(DR2), DQB1*0501, DPB1*0401; non-response has been shown
repeatedly to correlate with DRB1*03, DRB1*07, DQB1*02,
DPB1*1101 [29,30]. However, very little indeed is published on
HBV vaccine-induced immunogenicity regarding variation in
non-HLA genes [31]. Most of these studies are hampered by small
sample sizes and a limited number of markers/genes screened, so
we only have a snapshot understanding of what genetic factors are
implicated in the control of HBV vaccine immunogenicity.
Furthermore, different populations have been studied making
comparisons difficult, and virtually none of these associations have
been confirmed. Finally, although we know that peak anti-HBs
level predicts long-term vaccine efficacy, what genetic factors may
influence duration of protection has hardly been investigated and
we do not know whether the genetic control of short-term immune
responses as measured in most studies translate into durable
immunity – it is likely that different genetic mechanisms underlie
the control of immune memory.
This current study is, to our knowledge, the first project
assessing this large a number of (non-HLA based) candidate genes
and their possible effect on HBV vaccine-induced immunity. We
obtained results on a total of 715 single nucleotide polymorphisms
(SNPs) across 133 genes, and tested for association with peak anti-
HBs level (directly correlated with durability of anti-HBs response,
i.e. long-term vaccine efficacy, protection against infection and
persistent carriage) and anti-HBc status (indication of infection
despite vaccination) in a study sample of 662 infant vaccinees from
The Gambia who have been followed-up for close to two decades.
We report here on the findings from this study, together with a
replication study comprising 43 SNPs in 393 further individuals
from the same population.
Materials and Methods
Study participants
Recruitment was carried out in 2003 in the West Kiang region
in The Gambia as part of the survey to determine HBV vaccine
efficacy 19 years post vaccination, and in particular to evaluate of
the magnitude and duration of protective antibody responses
induced by infant HBV vaccination [9]. Findings from earlier
studies in the same region (1985, 1989, 1993, and 1998) including
information on demographics, medical background and epidemi-
ological data have been published previously [2,5–9]. Briefly,
children born within the area covered by the MRC Unit in
Keneba (West-Kiang, The Gambia) vaccinated within the HBV
vaccination programme were considered eligible for the present
study. The recruitment was restricted to non-infected individuals,
only confirmed non-immune children ,5 years old had been
recruited prior to 1985 and from there onwards all study
participants were vaccinated at birth, i.e. are deemed anti-HBc
negative (perinatal transmission of HBV infection is very rare in
this population[32]).
This genetic study was carried out in two stages: The first screen
study participants comprised all individuals identified as anti-HBc
positive on at least one survey (i.e. ever positive) and, where
possible, two randomly selected age-group matched consistently
anti-HBc negative individuals. All other individuals, who by
definition were anti-HBc negative, were included in the second
stage, which was designed with the aim to replicate the ‘top’ results
from the first screen. Exclusion criteria were: no information on
peak anti-HBs level or date, peak anti-HBs measurement time less
than one month after the last vaccination (anti-HBs is thought to
peak at 1 month after the last dose), no information on number of
doses of vaccine and age .5 yrs at time of last vaccination. Study
participants originated from three main villages Keneba, Manduar
and Kantonkunda and a small number of individuals from other
villages or visitors to the region, all of whom had been included in
the vaccine programme. Vaccination groups up to 2002 reflect
type of vaccine, administration route and time period during
which a regime was used (see Table 1); accordingly there is a direct
relationship between vaccine group and date of birth (i.e. age of
vaccinee). The number of individual belonging to vaccine group 6
was small (n=2) and these were thus excluded from the analysis.
The number of vaccine doses received was grouped into #3
(containing a small number of two and one dose recipients) versus
4 doses. An overview of selection/exclusion criteria is given in
Supplementary Figure S1.
We studied two outcome measures in the 1
st screen (i) peak anti-
HBs level as quantitative variable and (ii) anti-HBs status as binary
variable, and for the 2
nd screen peak anti-HBs level only.
Additional screen specific exclusion of samples and covariate
frequency distribution with corresponding geometric mean titer
(GMT) of peak anti-HBs for each of the two sample sets are
described below and are summarized in Table 1.
This project was approved by the joint Gambia Government/
MRC Ethics Committee, as well as LSHTM and Oxford
University (OXTREC) Ethics Committees. All subjects and/or
legal guardians provided written, informed consent.
1
st screen study participants. The total available sample
for the first screen with complete data on covariates was 662, these
were included in the assessment of peak anti-HBs level. The
number of individuals included in the analysis of anti-HBc status
was reduced to 594, because we decided to confine the analysis to
a clear-cut binary outcome of consistently anti-HBc positive versus
consistently negative individuals. Thus, we excluded individuals
who were reconverters (n=61; 9.3%), i.e. those shown to have lost
core-antibody positivity over the course of follow-up, and those
who presented with variable anti-HBc status over time (n=7). The
group of individuals with less than 3 doses of vaccine included two
individuals with two doses only. The mean age of the whole 1
st
screen sample was 13.4 years (range 1.2 to 22.9 years) and
consisted of 377 sibships with up to seven siblings, 27.1% of these
sibships comprised just one individual; relatedness was accounted
for in the analysis.
2
nd screen study participants. The sample available for
analysis for the 2
nd screen was 393 individuals with complete data
on covariates, the mean age was 7.4 years (range 1.1 to
16.2 years). These individuals tended to be younger and all were
consistently anti-HBc negative, due to the initial selection
procedure applied for the 1
st screen (see above). The group of
individuals with less than 3 doses of vaccine included six with two
doses and one with one dose. The 2
nd screen sample consisted of
277 sibships with up to five siblings, 42.2% of these contained only
one individual. There were no individuals representative of
vaccine group 1 and 2 in this sample (due to the younger mean
age) and because groups 3 and 6 consisted of very few individuals,
HBV Vaccine Genetics
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excluded.
Vaccinations and serological assessment
Vaccination types and regimes changed over time (as shown in
Table 1). The median measurement time between last vaccination
and peak antibody level assessment was 9 weeks (range 5.0 to
57.2 weeks). At each survey time point, concentrations of core
antibody (anti-HBc) and, if found to be positive, hepatitis B surface
antigen (HBsAg) and HBeAg were assessed, as described
previously [9].
Infection was defined as the presence of anti-HBc with at least
30% inhibition, as stipulated by the manufacturer (Sorin
Biochemica or DiaSorin). If infection was found only during a
single follow-up time point and was not confirmed subsequently,
the person was considered to have had a transient infection.
Carriage was defined as the detection of HBsAg on two separate
occasions at least six months apart. Primary vaccine failure was
defined as a peak anti-HBs response of ,10 mIU/mL; a
responder was defined as a vaccinee with a peak anti-HBs
response of $10 mIU/mL. The proportion of HBsAg positive
(n=21), anti-HBeAg positive (n=7) and persistent carriers (n=7)
in the total sample was too small for a subgroup analysis of these
parameters.
Genetic analysis
DNA extraction from whole blood or PBMCs was carried out
using a standard salting-out method [33]. Genotyping assays for
the initial screen were run on the Illumina BeadArray platform
(www.illumina.com). Our candidate gene selection criteria were
Table 1. Frequency distribution of outcome measures and covariates in 1
st and 2
nd screen sample sets with corresponding
geometric mean peak anti-HBs titer (GMT)
1st screen participants (n=662) 2nd screen participants (n=393)
Grouping N % GMT 95%CI N % GMT 95%CI
Age group [years] 0–5 51 7.7 180 106 306 118 30.0 200 141 284
5–10 120 18.1 436 289 658 175 44.5 900 660 1226
10–15 184 27.8 1957 1523 2515 96 24.4 3665 2631 5106
15–20 227 34.3 2195 1613 2986 4 1.0 5566 884 35039
.20 80 12.1 411 262 646 n/a
Gender male 317 47.9 1009 783 1300 207 52.7 703 519 951
female 345 52.1 1126 885 1432 186 47.3 978 712 1344
Village Keneba 368 55.6 1121 886 1418 186 47.3 891 646 1228
Manduar 150 22.7 1091 750 1587 81 20.6 957 596 1537
Kantonkunda+others 144 21.8 924 643 1329 126 32.1 662 448 980
Vaccination group 1 (1984/1985) 54 8.2 987 672 1449 n/a
2 (1984/1985) 43 6.5 443 279 705 n/a
3 (1984/1985) 45 6.8 163 92 290 excluded (n=3)
4 (1984–1992) 294 44.4 3263 2557 4165 80 20.4 4355 3068 6182
5 (1992–1993) 62 9.4 1049 705 1562 39 9.9 1757 1039 2973
6 (1992–1993) excluded (n=2)
7 (1993–2001) 164 24.9 314 224 442 274 69.7 453 351 586
Number of doses #32 7 3 41.2 567 432 744 118 30.0 266 184 384
43 8 9 58.8 1666 1342 2069 275 70.0 1334 1039 1713
Ethnicity Mandinka 636 96.1 1066 892 1274 367 93.4 823 656 1032
Other 26 3.9 1127 493 2572 26 6.6 808 319 2043
Vaccine response non-responder (,10IU/ml) 32 4.8 15 3.8
responder ($10IU/ml) 630 95.2 1403 1202 1638 378 96.2 1006 822 1231
Anti-HBc status always negative 462 69.8 1560 1280 1900 n/a
consistently positive 132 19.9 298 197 452 n/a
reconverter 61 9.2 1021 626 1666 n/a
variable 7 1.1 629 99 3984 n/a
Key: Vaccination groups: 1) HB-Vax 3620 mg im; 2) HB-Vax 1620 mgi m +262 mg id; 3) HB-Vax 362 mg id; 4) HB-Vax 4610ug im; 5) Recombivax 365 mgi m ;6 )
EnergixB 3610 mg im; 7) Hepacine 46(later 36)2 . 5mg im [9]. 95%CI: 95% confidence interval.
Notes on 1
st screen: The ‘Kantonkunda+others’ village group includes 33 individuals from other villages or visitors to the region. No individuals in vaccine group 6 were
present. The number of individuals with less than 3 doses includes three participants with only two doses of HBV vaccine.
Notes on 2
nd screen: As there were only four individuals aged .15 years, these were grouped with those aged 10–15 years. The ‘Kantonkunda+others’’ village group
contains 44 ‘others’. There were no individuals from vaccination groups 1 and 2; vaccine groups 3 and 6 were excluded from the analysis as they contained less than five
individuals in each. The number of individuals with less than 3 doses included a total of one individual with one dose, and six participants with two doses of HBV
vaccine.
doi:10.1371/journal.pone.0001898.t001
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with vaccine-induced antibody level (in particular with anti-HBs),
possible biological implication in immune-regulatory processes,
inclusion of gene families and coverage of regulatory pathways.
The selection of 768 single nucleotide polymorphism (SNPs) for
genotyping was based on HapMap frequency data, validation,
anticipated success rate on the Illumina platform, gene size,
distribution across loci, enrichment in coding changes, inclusion of
sequence 500 bp up- and down-stream of each gene. Just over
95% of our candidate polymorphisms were SNPs genotyped in
both Yoruba (YRI) and Caucasians (CEU) as part of the HapMap
project (http://www.hapmap.org/), many of these variants are tag
SNPs in either or both of these populations.
Linkage disequilibrium (LD) and haplotype blocks were assessed
using the Haploview programme (http://www.broad.mit.edu/
mpg/haploview/) applying default parameters according to
Gabriel et al [34]. To account for markers with low minor allele
frequency (MAF) we employed r
2 as measure of LD throughout
and considered an r
2 value of 0 to 0.5 as low, 0.5 to 0.75 as
intermediate and .0.75 as strong LD. The FASTSNP
programme (http://fastsnp.ibms.sinica.edu.tw/pages/input_
CandidateGeneSearch.jsp) was employed to establish whether
SNPs were of functional relevance [35].
The 2
nd screen genotyping was carried out using the Sequenom
platform (iPlex and hME; http://www.sequenom.de/). The aim
was to replicate the results from the first screen by concentrating
on the ‘top’ markers in the remainder of the sample set.
Statistical analysis
Validated demographic and serological data was available as an
Access 2000 database from the MRC’s long-term hepatitis B
vaccination programme [9]. All statistical analysis was conducted
using Stata software (version 9; StataCorp) and employed forward
regression models to determine the role of genetic markers on
outcomes, with inclusion of individual SNPs into the (multi-
marker) gene/locus models according to LD structure. No
adjustment for multiple comparisons was made. Almost 95% of
individuals were Mandinka, ethnicity was thus not considered
informative enough for stratification of the study cohort by ethnic
groups.
This society is polygamous, thus resulting in a complex pedigree
structure, e.g. presence of a large proportion of half-sibs.
Consequently, clustering by sibship was determined by maternal
ID in order to account for relatedness. For polymorphisms with a
low MAF heterozygotes and homozygotes were grouped for the
analysis if there were less than 10 individuals in the latter genotype
category by outcome measure. Genetic variation was entered in
the analysis as categorical genotype data with 11 representing
ancestral homozygotes, 12 representing heterozygotes and 22
representing variant homozygotes. Two outcome measures were
assessed: (i) peak anti-HBs level and (ii) anti-HBc status.
i) Peak anti-HBs. From the peak anti-HBs level we can
predict the persistence of antibody level at any time point
afterwards, peak anti-HBs is also a predictor of risk of infection
and persistent carriage. Peak anti-HBs was not normally
distributed and thus log-transformed for the analysis. Multiple
linear regression, including robust standard errors to account for
relatedness by sibship, was used to identify covariates associated
with log peak anti-HBs level. The model included as covariates the
logarithm of measurement time (i.e. duration of time between last
vaccination and peak anti-HBs measurement to account for the
exponential decay of anti-HBs over time), vaccine group (i.e. type,
regime, administration route, year), number of doses (#3 versus 4),
age group at recruitment (5 year intervals), village (Keneba,
Manduar, Kantonkunda+others), gender and relatedness. Results
are summarized as the ratio of the geometric mean titer (GMT),
associated 95% confidence intervals (CI) and P-values.
ii) Anti-HBc status. Consistent core antibody positive
individuals were defined as those who had been identified as
anti-HBc positive at any time point and remained positive at
subsequent surveys and compared to subjects who were
consistently negative for anti-HBc over the course of time;
reconverters and variables were excluded (see above). Multiple
conditional logistic regression, including robust standard errors to
account for relatedness by sibship, was used to identify covariates
associated with being core antibody positive. The model for anti-
HBc status accounted for peak anti-HBs level (as surrogate
measure for vaccine group, anti-HBs measurement time, number
of vaccine doses), age group at recruitment (5 year intervals),
village (Keneba, Manduar, Kantonkunda+others), and gender as
covariates. Results are reported as odds ratios (OR), with
associated 95% CI and P-values.
The statistical analysis for the 2
nd screen was carried out in an
identical manner to that of the 1
st screen for anti-HBs level as the
outcome. The distribution of covariates for the 2
nd screen was
slightly different in terms of age and vaccine group distribution (see
below).
Results
Genetic analysis of 1
st screen data
Overall 739/768 SNP assays produced good quality data
(failure rate 3.8%). Twenty SNPs were monomorphic or had
a MAF of ,1% and were excluded from the analysis. The
remaining SNPs were distributed across 133 candidate genes
with a varying number of markers per gene (shown in
supplementary Table S1), covering all chromosomes except 15
and 18. The average genotyping success rate across all markers
was 99.5% (ranging from 71.2–100.0%). Four SNPs had a failure
rate .10% and were excluded leaving a total of 715 SNPs for
analysis.
Hardy-Weinberg equilibrium (HWE) calculation was based on
one randomly selected individual from each sibship. Of the 715
SNPs available for the statistical analysis 40 (5.6%) were shown to
diverge from HWE (P range 1.5E-27 to 0.5). At the P,0.05 level
we expect to find approximately 36 SNPs to be out of HWE, the
observed number of markers diverging from HWE is therefore
comparable to the expected number. There was no obvious
clustering of SNPs out of HWE, or a trend for excess presence of
one particular genotype across these polymorphisms. Markers not
in HWE are only discussed further if a positive association with
either outcome measure was found.
Statistical analysis of 1
st screen data
i) peak anti-HBs level
Basic model for peak anti-HBs level for 1
st screen: In all models, including
the basic model (i.e. excluding genetic factors, see Table 2A), a
strong effect of vaccine group and measurement time was seen on
peak anti-HBs as quantitative outcome measure. Overall, the
adjusted GMT was between 60–94% lower in all vaccination
groups compared to the reference group 4 (P#0.001). This was
expected and previously described as part of the HBV vaccine
efficacy studies in this population [9]. The adjusted correlation
coefficient for the decline of anti-HBs level with time since last
vaccination (measurement time) was 20.99 (95%CI: 21.51 to
20.47). No effect was seen with number of vaccine doses (#3v s4 )
upon inclusion or exclusion of the few individuals with only two
doses of vaccine (data not shown). Village seemed to show a trend
towards association, with individuals born in Kantonkunda
HBV Vaccine Genetics
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level. This result did not change upon exclusion of the 33
individuals from other villages or visitors to the region, who had
been grouped with Kantonkunda for the analysis (data not shown).
Neither gender nor age at recruitment (range 1.2 to 22.9 years)
showed an effect on peak anti-HBs level.
Adjusted genetic models for peak anti-HBs for 1
st screen: Out of a total of 133
screened genes we identified host genetic variation in three
candidate genes to affect peak vaccine-induced antibody level
using a cut-off of size of effect (ratio of GMT) of ,0.6 or .1.5 and
P#0.001 in the multi-marker models adjusted for covariates,
namely: MAPK8, IL10RA, and IFNG (see Table 3). For these
t h r e eg e n e st h em u l t i - m a r k e rm o d e l si n d i c a t e das i m i l a r
modification of GMT, but with reduced significance compared
to single SNP models (data not shown).
IFNG: Carriage of the variant allele for s523, which is located just
outside the 39UTR, was associated with a two times increase in
anti-HBs level (P=0.0001), FastSNP predicts this polymorphism
to be of functional relevance. The two screened markers in
IFNG showed low pairwise LD (r
2=0.27), and the associated SNP
(s523) was not in LD with markers in neighbouring genes, i.e.
IRAK3 upstream, or IL26 and IL22 downstream. We therefore
suspect this to be an independent association within the IFNG
locus.
MAPK8 (JNK1): A SNPs in MAPK8, s419 (intronic), demonstrated
a linear trend of carriage of the variant allele with 40–60%
reduction in anti-HBs level (P=0.0003). A second marker, s421,
which is in almost complete LD with s419 (r
2=0.99) gave the
same results (data not shown). Both these SNPs showed low to
intermediate LD (r
2#0.5) with four neighboring markers
genotyped, but the possibility that another functional variant lies
upstream or downstream and is in LD with SNP s419 or s421
cannot be excluded.
IL10RA: In IL10RA only s481 (intron 6) was associated with
increased GMT of anti-HBs level and this appeared to be
heterozygote protection effect (GMTratio of 1.75, P=0.001). We
observed low LD across the whole length of this gene covered with
our set of four SNPs and no LD with neighboring genes tested, so
if s481 is in LD with a functional variant it is likely to be very
nearby.
Table 2. Basic models using outcome measures peak anti-HBs level for 1
st and 2
nd screen and anti-HBc status for 1
st screen only
Outcome: Peak anti-HBs level 1
st screen 2
nd screen
Covariates [baseline] Grouping
Adjusted
GMTratio 95%CI P
Adjusted
GMTratio 95%CI P
ln(measure time)
a 20.99
a 21.51 20.47 2.35E-04 21.25 21.81 20.69 1.78E-05
Vaccination group
b [4] 1 0.40 0.19 0.86 0.018 n/a
2 0.18 0.08 0.39 1.40E-05 n/a
3 0.06 0.03 0.15 1.93E-10 excluded (n=3)
5 0.42 0.25 0.7 0.001 0.47 0.23 0.97 0.041
7 0.15 0.04 0.52 0.003 0.30 0.10 0.88 0.028
Number of doses [3] 4 1.51 0.8 2.87 0.204 0.68 0.36 1.28 0.227
Age group in years
c [0–5] 5–10 0.63 0.27 1.45 0.278 1.59 0.71 3.56 0.262
10–15 0.52 0.13 2.05 0.345 2.05 0.58 7.26 0.264
15–20 1.00 0.25 4.01 0.999 2.78 0.47 16.26 0.256
.20 0.76 0.17 3.33 0.713 Combined with age group 15–20
Gender [male] female 0.9 0.67 1.22 0.494 1.18 0.82 1.7 0.374
Village [Keneba] Manudar 0.83 0.55 1.26 0.386 0.99 0.62 1.58 0.981
Kantonkunda + others 0.62 0.42 0.94 0.023 0.86 0.55 1.36 0.528
Outcome: Anti-HBc status 1
st screen
Covariates [baseline] Grouping Adjusted OR 95%CI P
ln(anti-HBs) 0.7 0.63 0.77 4.83E-13
Age group in years [0–5] 5–10 1.57 0.6 4.08 0.355
10–15 2.05 0.81 5.23 0.131
15–20 3.58 1.42 9.01 0.007
.20 2.88 1.06 7.83 0.038
Village [Keneba] Manduar 1.36 0.81 2.28 0.249
Kantonkunda + others 1.66 1.02 2.7 0.04
Gender [male] female 0.68 0.45 1.01 0.057
Key: GMTratio: Geometric mean peak anti-HBs titer relative to baseline by covariate (i.e. age group 0–5, number of doses #3, vaccine group 4, village Keneba, gender
male). ln(measurement time): time between last vaccination and peak anti-HBs measurement in weeks. 95%CI: 95% Confidence intervals. OR: odds ratio.
aThe decline of anti-HBs level with time since last vaccination (measurement time) is expressed as the decrease in peak anti-HBs level for a unit increase in
log(measurement time) with corresponding P-value and 95%CI, adjusted for all covariates.
bNotes on 2nd screen: Age .15 yrs grouped together; vaccine groups 3, and 6 excluded, groups 1 and 2 not present. For further details on sub-grouping and exclusion
of subcategories see Table 1 and text. Anti-HBs level had a dose-dependent effect on risk of core-conversion; re-converters and variable positives (n=61 and n=7,
respectively) were excluded from the analysis.
doi:10.1371/journal.pone.0001898.t002
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lesser effect on anti-HBs level, and those taken forward to the 2
nd
screen are shown in supplementary Table S2; this includes ITGAL
(see below and Table 3).
ii) anti-HBc status
Basic model for anti-HBc status for 1
st screen: In the basic model
employing the binary outcome measure of core antibody status
(see Table 2B) peak anti-HBs level (surrogate for vaccine group
and measurement time) clearly affected the risk of core-conversion,
with an about 30% increase in being core antibody positive per log
decrease of peak anti-HBs level (P=4.83E-13). The older age
groups (.15 years) were more likely to present as anti-HBc
positive. A trend towards risk of core-conversion was seen in
individuals born in Kantonkunda (excluding the ‘others’ did not
change this significantly, data not shown) and to an even lesser
extent in males compared with females.
Adjusted genetic models for anti-HBc positivity for 1
st screen: We identified
CD163 as gene to play a role in determining anti-HBc status
although polymorphisms in several other genes were also
associated with an increased/decreased risk of core-conversion
with a reduced size of effect or significance level (see Table 3). The
single SNP analysis showed a dose-dependent risk of core-
conversion with carriage of the minor allele for CD163 s503
(intron 12); in the multi-SNP analysis this effect seems to be
enhanced in the presence of s504 (Ile to Val change at codon
342, r
2=0.56 with s503) with an up to 7- or 4-fold higher risk of
core-conversion for those homozygous for the minor allele of
s503 and s504, respectively (Table 3). There was no to low LD
with markers further upstream in the same gene and its
neighbor GNB3, however, there may be further SNPs correlated
with s503 and/or s504 downstream in a region not covered in this
study.
Inclusion/exclusion of the seven persistent carriers from the
anti-HBc positives did not alter the findings for the basic or
adjusted genetic models significantly (data not shown).
Genetic analysis of 2
nd screen data
For the second round of genotyping we concentrated on those
SNPs that had been shown to increase/decrease the GMT of anti-
HBs level in the 1
st screen by a factor of 1.5 and/or be associated
at the level of P,0.005. Alternative SNPs were genotyped if
technical difficulties using the 2
nd screen Sequenom genotyping
platform were encountered. We also re-screened a few polymor-
phisms that had shown an effect on anti-HBc status (although
the remainder of our samples did not comprise any anti-HBc
positive individuals). A total of 50 ‘top’ SNPs were selected, as
listed in Supplementary Table S3, of these three failed at the
design stage and four failed outright for technical reasons. We
obtained good genotyping data for 43 of the ‘top’ SNPs
with an average genotyping success rate of 94.8% (ranging from
74.9–99.7%). One SNPs out of these 43 diverged from HWE at
the P=0.05 level.
Basic model for peak anti-HBs level for 2
nd screen. For
the 2
nd screen all models including the basic model (i.e. excluding
genetic factors, see Table 2A) showed an effect of vaccine
group and measurement time on anti-HBs level, as expected
and as seen in the 1
st screen. Age group, number of doses, gender
and village did not appear to influence the vaccine-induced
antibody level.
Adjusted genetic models for peak anti-HBs for 2
nd
screen. A summary of the results for the single SNP analysis
for the replication study is shown in supplementary Table S4. Out
of the total of 43 ‘top’ SNP re-screened we identified one SNP
(s595) in ITGAL that appeared to influence peak anti-HBs level.
The results for the s595 SNP are comparable in both screens (1
st
screen: s595_22 GMTratio of 1.71, P=0.013; 2
nd screen: s595_22
GMTratio of 2.15, P=0.011; Table 3). The s595 polymorphism is
a non-synonymous coding change in exon 21 (R791T) and is
predicted to affect splicing regulation (FASTSNP prediction).
R791T is not in LD with any of the other four screened SNPs in
ITGAL (r
2#0.1), we thus hypothesize that this is an independent
association of a genetic variant that is likely to be functionally
relevant.
Other markers screened in the 2
nd sample set appeared to
increase/decrease the GMT level by more than 1.5-fold, but only
showed a trend for association (see supplementary Table S4).
An assessment vaccine non-response (anti-HBs ,10IU/ml,
primary vaccine failure) was not possible due to lack of power
given the small number of non-responders present (N=47 in 1
st
and 2
nd screen combined). The great majority of study participants
were of Mandinka origin and ethnicity was not adjusted for in the
analysis. However, inclusion/exclusion of the 26 individuals of
other ethnicity from the analysis did not alter significantly the
results for the basic or adjusted models for peak anti-HBs level or
anti-HBc status (data not shown).
Discussion
Hepatitis B vaccine-induced immunity is promoted by the
presentation of HBsAg via HLA class II molecules on antigen-
presenting cells to CD4 T helper cells, thereby triggering HBsAg-
specific B cells to proliferate and differentiate into anti-HBs
producing cells (primary immune response). Longer term both
memory T and B cells are generated, which are responsible for
subsequent anti-HBs release in response to later infections
(secondary immune responses). Immune memory to HBV is
crucially dependent on this rapid antibody release to neutralize the
challenge posed by circulating virus. Very little is known about
how durable immune memory is maintained, especially in the
absence of often undetectable primary vaccine-induced anti-HBs
level several years post immunization. However, peak anti-HBs
level induced by vaccination is directly related to a uniform decay
of antibody level over time irrespectively of population, and
predictive of vaccine efficacy long-term[10]. In The Gambia
protection against infection was reported to be 83.4% and against
persistent carriage to be 96.5% 19 years post vaccination [9]. The
present study aimed to investigate whether host genetic factors
affect durable vaccine-induced immunity (as predicted by peak
anti-HBs level) to HBV infection in The Gambia. An initial screen
obtained results on 715 SNPs in 133 genes in 662 infant vaccinees
and the replication screen comprised data on 43 SNPs in 393
individuals from the same population.
Based on our basic models, without genetic factors, our overall
findings regarding the effect of vaccine group, measurement time,
vaccine dose, age group, village and gender were as expected for
both our outcome measures and are in line with previous surveys
in the West-Kiang region [9]. We saw a strong effect of vaccine
group (reflecting vaccine type, regime, route and year of
administration) and time elapsed between last vaccine dose and
measurement of peak anti-HBs (measurement time) on peak anti-
HBs level (Table 2A). None of the other covariates influenced
vaccine-induced antibody level substantially.
Individuals positive for anti-HBc despite vaccination in infancy
are considered to be core-converters or to have had a
‘breakthrough’ infection. Because all individuals included in our
study were considered anti-HBc negative at the time of
recruitment, we believe that bias due to infection prior to
immunization is not an issue in our analysis. We assessed anti-
HBV Vaccine Genetics
PLoS ONE | www.plosone.org 7 March 2008 | Volume 3 | Issue 3 | e1898HBc status in the initial screen only and observed that anti-HBs
level (employed as surrogate for vaccine group and measurement
time) had the strongest effect on anti-HBc status, whilst gender and
village only showed weak associations (Table 2B), as expected.
Older individuals appeared more prone to core-conversion, and
this higher risk in older age groups could be due to either
decreased level of vaccine-induced anti-HBs level or an increased
level of exposure through sexual transmission (especially through
contact with unvaccinated individuals) or both. Unfortunately we
do not have any measure of exposure, other than age as potential
indicator of onset of sexual activity, and this could have biased our
findings. Due to small numbers present we excluded individuals
who had re-converted or presented with variable anti-HBc results,
although these would be an interesting sub-group for further
investigation.
The HLA region is the most extensively studied area to date
with regard to HBV vaccine-induced immunity and relatively
consistent data has been reported [29–31]. However, reports on
other candidate loci are very limited. Polymorphisms in members
of the IL1 gene family, IL2, IL4, IL6, IL10, IL12b, TNFa, GNB3,
and haptoglobin have all been implicated in affecting the
magnitude or kinetics of HBV vaccine-induced antibody response
or lymphocyte proliferation [36–42]. We concentrated our focus
mostly on novel candidate genes outside the MHC region,
although our 133 screened genes did include the above mentioned
previously screened genes with exception of TNFa and IL2 (see
Supplementary Table S1). Our candidate gene selection was based
on molecules that are known or likely to influence the regulation of
HBV vaccine-induced immune responses such as those involved in
pathogen uptake and recognition, antigen processing and
presentation, as well as effector and memory T and B cell
function (for full list see supplementary Table S1). We hypothesize
that host genetic variation could affect increased/decreased peak
anti-HBs level, thus indirectly influencing the risk of core
conversion, or directly affect susceptibility to infection despite
vaccination (as well as potentially re-conversion) and there may be
interaction between genes affecting these outcomes (for further
details see supplementary Figure S2).
In addition to vaccine group and measurement time (and to a
lesser degree village) we found genetic factors to affect our
outcomes. Through our 1
st screen we identified variation in three
candidates (MAPK8, IFNG and IL10RA) that play a role in HBV
vaccine-induced immunity by affecting the peak anti-HBs level
and polymorphisms in CD163 appeared to affect anti-HBc status
(all analyses adjusted for covariates, GMTratio or OR of ,0.6 or
.1.5 and P#0.001; Table 3). These and further SNPs in other
genes showing reduced size of effect or significance level we
followed-up in a 2
nd screen (see supplementary Table S2). We did
not confirm any previously reported associations in our native
African population.
IFNc is produced by activated T lymphocytes in response to
intracellular pathogen challenge. It plays a central role in immune-
regulatory processes, e.g. by activating macrophages and
potentiating antiviral effects of type I IFNs, and thus is crucial in
the cell-mediated immunity. A recent study by Yang et al showed
that persistent HBV carriers mounted a detectable HBV-specific
IFNc response to a HBV-derived DNA vaccine and this response
was observed for at least 40 weeks as a function of CD4+ memory
T-cells [43]. Our result suggests that genetically determined
differences in IFNc activity could impact on the magnitude of
immune responses to HBV vaccination.
MAPK8 (JNK1) is a kinase which functions within the TLR
pathway by promoting the phosphorylation of transcription factors
such as c-Jun and ATF2, following stimulation with pro-
inflammatory cytokines. A study by Vanlandschoot and colleagues
reported reduced phosphorylation of MAPK8 kinase in response
to rHBsAg in LPS-stimulated PBMCs [44]. It appears that
MAPK8 is primarily involved in the differentiation of T helper
into Th1 cells and maintaining their survival during antiviral
immune responses [45]. This Th1 mediated favoring of cell-
mediated immune responses could be a possible mechanism
underlying the association MAPK8 variation with reduced
antibody generation following HBV vaccination.
The involvement of IL10RA in immune responses induced by
HBV vaccination is also plausible, given that IL10RA is a receptor
which mediates the effects of IL10, and IL10 was shown to
correlate with immune responses to HBV vaccination [41]. We
observed IL10RA variation to have a beneficial effect by leading to
increased vaccine-induced anti-HBs level.
The risk of core-conversion despite vaccination was substantially
increased in a dose-dependent manner by SNPs in CD163 in our
study population. CD163 is a macrophage hemoglobin scavenger
receptor involved in acute phase response regulation; it can be
induced by IL6, IL10, TLR2 and TLR5, and is suppressed by pro-
inflammatory mediators including IFNc and TNFa. [46]. Reduced
levels of IFNc and TLRs may therefore lead to increased level of
CD163 and raised level of CD163 have been reported in patients
with persistent hepatitis infection [47]. Our dataset contained seven
carriers, but our findings did not change significantly upon inclusion
or exclusion of these individuals.
Overall the findings from the replication study did not provide
support for the three strongest associations identified in the first
screen, perhaps in part as a result of the smaller sample size in the
replication study. However, the 2
nd screen replicated an
association with host genetic variation in ITGAL, a gene which
did show association in the 1
st screen albeit at a reduced
significance level; evidence of correlation with vaccine-induced
antibody level was seen for s595. This SNP is a common non-
synonymous coding change (R719T; rs2230433; MAF=38%) and
a similar effect size, i.e. an about 2-fold increase in anti-HBs level,
was observed in both screens in individuals homozygote for the
variant allele encoding for Threonine (1
st screen: s595_22
GMTratio of 1.71, P=0.013; 2
nd screen s595_22 GMTratio of
2.15, P=0.011, see Table 3). Our result for this polymorphism is
thus the only true replication in the present study. However, we
cannot exclude the possibility of this being a chance finding given
the number of tests carried out. Lymphocyte function-associated
antigen-1 (LFA1) consists of two subunits ITGAL (also known as
LFA1A or CD11a) and ITGB2. ITGAL binds to ICAMs and
regulates processes such as leukocyte-endothelial cell interaction,
cytotoxic T-cell mediated killing, and antibody dependent killing
by granulocytes and monocytes. Despite its central role in immune
cell interaction no study assessing responses to viral or vaccine
challenges prior to this appears to have assessed host genetic
variation in ITGAL. The R791T variant lies within the integrin-
alpha-2 domain of the gene, which forms interactions with EGF2,
FG-GAP and Integrin_B_tail domains and this SNP is predicted
to be involved in splicing regulation, i.e. to play an important role
functionally. It would now be of interest to assess this R791T
variant for association in an independent sample set of HBV
vaccinees or with responses to other vaccines or other diseases that
are immunologically mediated.
Lack of power due to small sample numbers prevented us from
assessing possible genetic effects on vaccine non-response (primary
vaccine failure). Almost 95% of our study population was
Mandinka. Ethnicity was not adjusted in our analysis, but
inclusion/exclusion of individuals of other ethnic origin did not
change any of our results significantly.
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polymorphisms tested in the second sample is small and for
technical reasons we could not obtain data for all ‘top’ SNPs
identified through the 1
st screen. The sample size was about 40%
smaller and only one out of our two outcome measures, peak anti-
HBs level, could be assessed. The reduced power may explain why
our findings from the 2
nd screen showed reduced level of
significance, although the effect size was comparable for a number
of markers followed-up. It is possible that natural boosting through
exposure to HBV is a deter-
minant of anti-HBs persistence and we had no means of
addressing this specifically in our study. However, a recent vaccine
boost study in The Gambia reported on low pre-boost anti-HBs
levels suggesting that natural boosting is likely to play a limited role
[12].
The strength of our study lies primarily in the availability of good
serological and demographic data from infant HBV vaccinees
followed up long-term. There is no comparable sample cohort in
Africa as far as we are aware. The sole similar study of HBV vaccine
efficacy long-term is the Qidong HBV vaccine trial in China, for
which data has only been published based on the 5-year follow-up so
far [48]. A novel aspect of this present project is the reasonably large
number of polymorphisms (715) genotyped across a total of 133
genes located outside the MHC region, the great majority of which
have never before been tested as candidate genes in HBV vaccine-
induced immunity. We believe it is important to concentrate on
novel candidate genes, given that the heritability of non-HLA genes
has been estimated to range between 35–50% for immunity induced
by HBV vaccination [16,17].
Findings from studies such as this will help us to increase our
understanding of mechanisms underlying vaccine-induced immu-
nity and possible natural immunity to infection. This could lead to
the development of genetic markers as correlates of protection.
More importantly this type of investigation could help the
development of new and improved vaccines, e.g. through use of
adjuvants targeting pathways identified through genetic studies,
that could eventually lead to life-long protection and reduce the
proportion of vaccine failures.
Supporting Information
Figure S1 Schematic representation of role of host genetic factors
in vaccine-induced immunity to HBV. This figure is a schematic
diagram of HBV vaccine-induced immunity assessment employing
peak anti-HBs level and anti-HBc status as outcome measures.
Assuming host genetic variation (here SNP1) correlates with
increased/decreased peak anti-HBs level, this in turn indirectly
and inversely affects increased/decreased risk of core conversion. To
determine whether SNP1 also directly affects anti-HBc status we test
for association with anti-HBc status whilst adjusting for anti-HBs
level. Simultaneously, there may be other polymorphisms (here
SNP2), exerting a direct effect on the risk of core-conversion. There
may or may not be interaction between the genes in which these
SNPs are located. Additionally, genetic variants modulating the
immune-response to HBV vaccination may also affect susceptibility
to infection, or other polymorphisms (SNP3) or confounders may
lead to a countereffectby increasing the likelihood of infection inthe
presence of protective vaccine-induced antibody, thus further
complicating this scenario. Finally, coreantibodypositive individuals
may over time re-convert, which could be controlled directly or
indirectly through genetic factors. In our study only vaccinated
individuals with no indication of infection prior to immunization
were included, as such there was no scope to assess susceptibility to
infection, but simultaneously we believe there was no bias due to
infection at the time of recruitment. Furthermore, we excluded
individuals who lost anti-HBc positivity or had presented with
variable anti-HBc status over the course of follow-up in order to
work with a clear-cut distinction of those consistently positive versus
consistently negative for anti-HBc.
Found at: doi:10.1371/journal.pone.0001898.s001 (0.06 MB TIF)
Figure S2 Outline of study set-up with sample selection and
exclusion criteria. For further details see Materials and Methods
(study participants).
Found at: doi:10.1371/journal.pone.0001898.s002 (0.06 MB TIF)
Table S1 Details for SNPs in 1st screen
Found at: doi:10.1371/journal.pone.0001898.s003 (0.16 MBXLS)
Table S2 Single SNP analysis results for 1nd screen for markers
taken forward to 2nd screen
Found at: doi:10.1371/journal.pone.0001898.s004 (0.04 MBXLS)
Table S3 Details for SNPs in 2nd screen
Found at: doi:10.1371/journal.pone.0001898.s005 (0.03 MBXLS)
Table S4 Single SNP analysis results for 2nd screen
Found at: doi:10.1371/journal.pone.0001898.s006 (0.03 MBXLS)
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